| abstract |
The present invention is directed to compositions, methods of use, and processes for the synthesis related to 3-(( S )-l-(dimethylamino)ethyl)phenyl methyl-(( R )- 1 -phenylpropan-2 yl)carbamate, and its pharmaceutically acceptable salt forms, including the hydrogen fumarate salt. The present invention also relates to a novel form polymorph of 3-(( S )-l- (dimethylamino)ethyl)phenyl methyl-(( R )- 1 -phenylpropan-2 yl)carbamate, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure. |